High-dose contrast agent administration during complex coronary angioplasty

Abstract

To examine the necessity and consequences of high-dose contrast media administration during coronary angioplasty, the records of 730 consecutive patients over a 6-month period were reviewed. The 54 patients (7%) requiring contrast agent doses ≥400 ml were examined in detail. The mean contrast dose in this group was 496 ± 76 ml (range 400 to 785 ml). Their mean age was 63 ± 11 years (range 36 to 83 years), 10 patients had diabetes mellitus (19%), and four patients had a baseline creatinine level ≥1.5 mg/dl (7%). Following coronary angioplasty, the serum creatinine rose from 1.1 ± 0.2 to 1.2 ± 0.3 ( p = 0.08). The creatinine rose ≥0.5 mg/dl in six patients (11%) and ≥1.0 mg/dl in one patient (2%). Five of these six patients had either diabetes mellitus, baseline renal insufficiency, or both. Oliguria was not observed. The most important procedural factors contributing to the high doses of contrast media were multilesion and multivessel angioplasty in 96% and 83% of patients, respectively, prior bypass surgery in 52%, and combined diagnostic cardiac catheterization and angioplasty in 13%. Thus renal dysfunction following high-dose contrast agent administration during complex coronary angioplasty is infrequently associated with nephrotoxicity. Whenever possible, contrast doses in patients with diabetes mellitus and renal insufficiency should be minimized.